BioSpace News Archive

GT Biopharma, Inc. announced that Dr. Jeffrey Miller, MD, GT Biopharma’s Consulting Chief Medical Officer and Consulting Chief Scientific Officer, will participate in a fireside chat and the Keynote Session: KOL roundtable discussion at H.C. Wainwright’s Immune Cell Engager Conference taking place August 17, 2023.

The U.S. Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted unanimously 10 to 0 to recommend routine use of Sanofi and AstraZeneca’s Beyfortus™ for the prevention of respiratory syncytial virus lower respiratory tract disease for newborns and infants below 8 months of age born during or entering their first RSV season.

Kura Oncology, Inc. reported second quarter 2023 financial results and provided a corporate update.

Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced financial results for the second quarter ended June 30, 2023, and highlighted recent Company progress.

Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today reported recent business progress and financial results for the second quarter 2023.

Collegium Pharmaceutical, Inc., a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, reported its financial results for the quarter ended June 30, 2023, and provided a corporate update.

Inozyme Pharma, Inc. announced that the Company granted stock options to new employees to purchase shares of the Company’s common stock, pursuant to the Company’s 2023 Inducement Stock Incentive Plan, each as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635.

Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the second quarter 2023 on Tuesday, August 8, 2023, after market close.

Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today reported financial results and business highlights for the second quarter 2023.

Sight Sciences, Inc., an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients’ lives, reported financial results for the second quarter ended June 30, 2023 and reaffirmed guidance for full year 2023.